Miguel
Fernández de Sanmamed Gutiérrez
Consultor Médico
Publicacións (108) Publicacións de Miguel Fernández de Sanmamed Gutiérrez
2024
-
PD-1H/VISTA mediates immune evasion in acute myeloid leukemia
The Journal of clinical investigation, Vol. 134, Núm. 3
-
Phase 1, first-in-human study of TYRP1-TCB (RO7293583), a novel TYRP1-targeting CD3 T-cell engager, in metastatic melanoma: active drug monitoring to assess the impact of immune response on drug exposure
Frontiers in Oncology, Vol. 14
-
Sequential immunotherapy and targeted therapy for metastatic BRAF V600 mutated melanoma: 4-year survival and biomarkers evaluation from the phase II SECOMBIT trial
Nature Communications, Vol. 15, Núm. 1
-
Up-regulated PLA2G10 in cancer impairs T cell infiltration to dampen immunity
Science immunology, Vol. 9, Núm. 94, pp. eadh2334
-
Whole exome sequencing and machine learning germline analysis of individuals presenting with extreme phenotypes of high and low risk of developing tobacco-associated lung adenocarcinoma
eBioMedicine, Vol. 102
2023
-
A first-in-human study of the fibroblast activation protein-targeted, 4-1BB agonist RO7122290 in patients with advanced solid tumors
Science translational medicine, Vol. 15, Núm. 695, pp. eabp9229
-
CD137 (4-1BB)-Based Cancer Immunotherapy on Its 25th Anniversary
Cancer discovery, Vol. 13, Núm. 3, pp. 552-569
-
Intratumoral BO-112 in combination with radiotherapy synergizes to achieve CD8 T-cell-mediated local tumor control
Journal for immunotherapy of cancer, Vol. 11, Núm. 1
-
Intratumoral Gene Transfer of mRNAs Encoding IL12 in Combination with Decoy-Resistant IL18 Improves Local and Systemic Antitumor Immunity
Cancer immunology research, Vol. 11, Núm. 2, pp. 184-198
-
Mass cytometry to characterize the immune lung cancer microenvironment
Methods in Cell Biology, Vol. 174, pp. 31-41
-
PSA reactivity in extracellular microvesicles to commercial immunoassays
Clinica Chimica Acta, Vol. 543
-
Reply to letter to the editor “Bureaucracy or Streamlining the Rules in “Good Clinical Practice (GCP)” - Has Equipoise Occurred?” by H. K. Kotikonda, V. G. Jonnalagadda and S. R. Venna
Annals of Oncology
-
Sequencing of Ipilimumab Plus Nivolumab and Encorafenib Plus Binimetinib for Untreated BRAF -Mutated Metastatic Melanoma (SECOMBIT): A Randomized, Three-Arm, Open-Label Phase II Trial
Journal of Clinical Oncology, Vol. 41, Núm. 2, pp. 212-221
-
Streamlining clinical research: an ESMO awareness call to improve sponsoring and monitoring of clinical trials
Annals of Oncology, Vol. 34, Núm. 1, pp. 70-77
-
mRNAs encoding IL-12 and a decoy-resistant variant of IL-18 synergize to engineer T cells for efficacious intratumoral adoptive immunotherapy
Cell Reports Medicine, Vol. 4, Núm. 3
2022
-
A Therapeutically Actionable Protumoral Axis of Cytokines Involving IL-8, TNFα and IL-1β
Cancer Discovery, Vol. 12, Núm. 9, pp. 2140-2157
-
Charting roadmaps towards novel and safe synergistic immunotherapy combinations
Nature Cancer, Vol. 3, Núm. 6, pp. 665-680
-
PD-L1 Crosslinking as a New Strategy of 4-1BB Agonism Immunotherapy
Clinical Cancer Research, Vol. 28, Núm. 15, pp. 3182-3184
-
Quantitative tissue analysis and role of myeloid cells in non-small cell lung cancer
Journal for ImmunoTherapy of Cancer, Vol. 10, Núm. 7
-
Three-dimensional colon cancer organoids model the response to CEA-CD3 T-cell engagers
Theranostics, Vol. 12, Núm. 3, pp. 1373-1387